Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

NCT03736369 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

263

Enrollment

INDUSTRY

Sponsor class

Conditions

Erosive Esophagitis

Interventions

DRUG: DWP14012 40mg
DRUG: DWP14012 40mg placebo
DRUG: Esomeprazole 40mg
DRUG: Esomeprazole 40mg placebo

Sponsor

Daewoong Pharmaceutical Co. LTD.